Christopher M. Waters
Research Subjects
Christopher M. Waters has a total of 158 co-authors. Here are the top co-authors by number of shared publications:
- Derek D. Norman
Department of Physiology, University of Tennessee Health Science Center, Memphis, TN 38163, USA
6 shared publications - Erzsébet Szabó
Department of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4032 Debrecen, Hungary
6 shared publications Gabor J. Tigyi
6 shared publications- Junming Yue
Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, USA
6 shared publications Louisa Balazs
6 shared publicationsRenukadevi Patil
6 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (181) , 260058
Bench evidence, bedside uncertainty: hyperoxia, mechanical ventilation and lung injury
The management of respiratory failure often necessitates the use of supplemental oxygen and mechanical ventilation, both crucial interventions in critical care. However, this combination of hyperoxia (defined as exposure to supra-atmospheric levels of oxygen) and mechanical ventilation can lead to significant additional lung injury. The aim of this review is to synthesise current evidence defining how hyperoxia primes the adult lung for increased susceptibility to the development of lung injury during mechanical ventilation and to contextualise these mechanisms within contemporary clinical research and practice. We review experimental and translational studies elucidating the interplay between oxidative stress, cytoskeletal remodelling, inflammation, and alveolar–capillary barrier dysfunction, highlighting how these processes initiate or amplify pre-existing lung injury. We also examine current approaches to oxygen therapy, both as a standalone intervention and in the context of ventilator management. While the injurious role of hyperoxia in animal models is highly consistent and reproducible, clinical trials have been less consistent in directly linking hyperoxia exposure to increased patient mortality. Although clinical trials comparing liberal versus conservative oxygen strategies have yielded conflicting results over decades, emerging mechanistic insights from pre-clinical models may help identify patient subpopulations at greatest risk for hyperoxia-associated lung injury. By integrating evidence from basic science and clinical studies, this review underscores the importance of judicious oxygen titration to mitigate iatrogenic lung injury and optimise outcomes in critically ill patients.
- 1 July 2026
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 35 (181) , 260058
Open AccessBench evidence, bedside uncertainty: hyperoxia, mechanical ventilation and lung injury
The management of respiratory failure often necessitates the use of supplemental oxygen and mechanical ventilation, both crucial interventions in critical care. However, this combination of hyperoxia (defined as exposure to supra-atmospheric levels of oxygen) and mechanical ventilation can lead to significant additional lung injury. The aim of this review is to synthesise current evidence defining how hyperoxia primes the adult lung for increased susceptibility to the development of lung injury during mechanical ventilation and to contextualise these mechanisms within contemporary clinical research and practice. We review experimental and translational studies elucidating the interplay between oxidative stress, cytoskeletal remodelling, inflammation, and alveolar–capillary barrier dysfunction, highlighting how these processes initiate or amplify pre-existing lung injury. We also examine current approaches to oxygen therapy, both as a standalone intervention and in the context of ventilator management. While the injurious role of hyperoxia in animal models is highly consistent and reproducible, clinical trials have been less consistent in directly linking hyperoxia exposure to increased patient mortality. Although clinical trials comparing liberal versus conservative oxygen strategies have yielded conflicting results over decades, emerging mechanistic insights from pre-clinical models may help identify patient subpopulations at greatest risk for hyperoxia-associated lung injury. By integrating evidence from basic science and clinical studies, this review underscores the importance of judicious oxygen titration to mitigate iatrogenic lung injury and optimise outcomes in critically ill patients.
- Open Access
- 1 September 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (3) , L327-L340
Stem cells, cell therapies, and bioengineering in lung biology and diseases 2023
Repair and regeneration of a diseased lung using stem cells or bioengineered tissues is an exciting therapeutic approach for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence from preclinical models suggests that mesenchymal stromal cells, which are not normally resident in the lung, can be used to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating the use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those involving stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in our understanding of the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise during lung development and participate in normal and pathological remodeling after lung injury. For the 2023 Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference, scientific symposia were chosen to reflect the most cutting-edge advances in these fields. Sessions focused on the integration of “omics” technologies with function, the influence of immune cells on regeneration, and the role of the extracellular matrix in regeneration. The necessity for basic science studies to enhance fundamental understanding of lung regeneration and to design innovative translational studies was reinforced throughout the conference.
- 1 September 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 327 (3) , L327-L340
Open AccessStem cells, cell therapies, and bioengineering in lung biology and diseases 2023
Repair and regeneration of a diseased lung using stem cells or bioengineered tissues is an exciting therapeutic approach for a variety of lung diseases and critical illnesses. Over the past decade, increasing evidence from preclinical models suggests that mesenchymal stromal cells, which are not normally resident in the lung, can be used to modulate immune responses after injury, but there have been challenges in translating these promising findings to the clinic. In parallel, there has been a surge in bioengineering studies investigating the use of artificial and acellular lung matrices as scaffolds for three-dimensional lung or airway regeneration, with some recent attempts of transplantation in large animal models. The combination of these studies with those involving stem cells, induced pluripotent stem cell derivatives, and/or cell therapies is a promising and rapidly developing research area. These studies have been further paralleled by significant increases in our understanding of the molecular and cellular events by which endogenous lung stem and/or progenitor cells arise during lung development and participate in normal and pathological remodeling after lung injury. For the 2023 Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Diseases Conference, scientific symposia were chosen to reflect the most cutting-edge advances in these fields. Sessions focused on the integration of “omics” technologies with function, the influence of immune cells on regeneration, and the role of the extracellular matrix in regeneration. The necessity for basic science studies to enhance fundamental understanding of lung regeneration and to design innovative translational studies was reinforced throughout the conference.
- 1 March 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 326 (3) , L367-L376
Two-pore potassium channel TREK-1 (K2P2.1) regulates NLRP3 inflammasome activity in macrophages
Because of the importance of potassium efflux in inflammasome activation, we investigated the role of the two-pore potassium (K2P) channel TREK-1 in macrophage inflammasome activity. Using primary alveolar macrophages and bone marrow-derived macrophages from wild-type and TREK-1–/– mice, we measured responses to inflammasome priming (using LPS) and activation (LPS + ATP). Our results suggest that TREK-1 is an important regulator of NLRP3 inflammasome activation in macrophages.
- 1 March 2024
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 326 (3) , L367-L376
Two-pore potassium channel TREK-1 (K2P2.1) regulates NLRP3 inflammasome activity in macrophages
Because of the importance of potassium efflux in inflammasome activation, we investigated the role of the two-pore potassium (K2P) channel TREK-1 in macrophage inflammasome activity. Using primary alveolar macrophages and bone marrow-derived macrophages from wild-type and TREK-1–/– mice, we measured responses to inflammasome priming (using LPS) and activation (LPS + ATP). Our results suggest that TREK-1 is an important regulator of NLRP3 inflammasome activation in macrophages.
- Open Access
- 15 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17501
Deficiency of Acute-Phase Serum Amyloid A Exacerbates Sepsis-Induced Mortality and Lung Injury in Mice
Serum amyloid A (SAA) is a family of proteins, the plasma levels of which may increase >1000-fold in acute inflammatory states. We investigated the role of SAA in sepsis using mice deficient in all three acute-phase SAA isoforms (SAA-TKO). SAA deficiency significantly increased mortality rates in the three experimental sepsis mouse models: cecal ligation and puncture (CLP), cecal slurry (CS) injection, and lipopolysaccharide (LPS) treatments. SAA-TKO mice had exacerbated lung pathology compared to wild-type (WT) mice after CLP. A bulk RNA sequencing performed on lung tissues excised 24 h after CLP indicated significant enrichment in the expression of genes associated with chemokine production, chemokine and cytokine-mediated signaling, neutrophil chemotaxis, and neutrophil migration in SAA-TKO compared to WT mice. Consistently, myeloperoxidase activity and neutrophil counts were significantly increased in the lungs of septic SAA-TKO mice compared to WT mice. The in vitro treatment of HL-60, neutrophil-like cells, with SAA or SAA bound to a high-density lipoprotein (SAA-HDL), significantly decreased cellular transmigration through laminin-coated membranes compared to untreated cells. Thus, SAA potentially prevents neutrophil transmigration into injured lungs, thus reducing exacerbated tissue injury and mortality. In conclusion, we demonstrate for the first time that endogenous SAA plays a protective role in sepsis, including ameliorating lung injury.
- 15 December 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (24) , 17501
Open AccessDeficiency of Acute-Phase Serum Amyloid A Exacerbates Sepsis-Induced Mortality and Lung Injury in Mice
Serum amyloid A (SAA) is a family of proteins, the plasma levels of which may increase >1000-fold in acute inflammatory states. We investigated the role of SAA in sepsis using mice deficient in all three acute-phase SAA isoforms (SAA-TKO). SAA deficiency significantly increased mortality rates in the three experimental sepsis mouse models: cecal ligation and puncture (CLP), cecal slurry (CS) injection, and lipopolysaccharide (LPS) treatments. SAA-TKO mice had exacerbated lung pathology compared to wild-type (WT) mice after CLP. A bulk RNA sequencing performed on lung tissues excised 24 h after CLP indicated significant enrichment in the expression of genes associated with chemokine production, chemokine and cytokine-mediated signaling, neutrophil chemotaxis, and neutrophil migration in SAA-TKO compared to WT mice. Consistently, myeloperoxidase activity and neutrophil counts were significantly increased in the lungs of septic SAA-TKO mice compared to WT mice. The in vitro treatment of HL-60, neutrophil-like cells, with SAA or SAA bound to a high-density lipoprotein (SAA-HDL), significantly decreased cellular transmigration through laminin-coated membranes compared to untreated cells. Thus, SAA potentially prevents neutrophil transmigration into injured lungs, thus reducing exacerbated tissue injury and mortality. In conclusion, we demonstrate for the first time that endogenous SAA plays a protective role in sepsis, including ameliorating lung injury.
- Open Access
- 13 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Spatial metabolomics reveals glycogen as an actionable target for pulmonary fibrosis
Matrix assisted laser desorption/ionization imaging has greatly improved our understanding of spatial biology, however a robust bioinformatic pipeline for data analysis is lacking. Here, we demonstrate the application of high-dimensionality reduction/spatial clustering and histopathological annotation of matrix assisted laser desorption/ionization imaging datasets to assess tissue metabolic heterogeneity in human lung diseases. Using metabolic features identified from this pipeline, we hypothesize that metabolic channeling between glycogen and N-linked glycans is a critical metabolic process favoring pulmonary fibrosis progression. To test our hypothesis, we induced pulmonary fibrosis in two different mouse models with lysosomal glycogen utilization deficiency. Both mouse models displayed blunted N-linked glycan levels and nearly 90% reduction in endpoint fibrosis when compared to WT animals. Collectively, we provide conclusive evidence that lysosomal utilization of glycogen is required for pulmonary fibrosis progression. In summary, our study provides a roadmap to leverage spatial metabolomics to understand foundational biology in pulmonary diseases.
- 13 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-18
Open AccessSpatial metabolomics reveals glycogen as an actionable target for pulmonary fibrosis
Matrix assisted laser desorption/ionization imaging has greatly improved our understanding of spatial biology, however a robust bioinformatic pipeline for data analysis is lacking. Here, we demonstrate the application of high-dimensionality reduction/spatial clustering and histopathological annotation of matrix assisted laser desorption/ionization imaging datasets to assess tissue metabolic heterogeneity in human lung diseases. Using metabolic features identified from this pipeline, we hypothesize that metabolic channeling between glycogen and N-linked glycans is a critical metabolic process favoring pulmonary fibrosis progression. To test our hypothesis, we induced pulmonary fibrosis in two different mouse models with lysosomal glycogen utilization deficiency. Both mouse models displayed blunted N-linked glycan levels and nearly 90% reduction in endpoint fibrosis when compared to WT animals. Collectively, we provide conclusive evidence that lysosomal utilization of glycogen is required for pulmonary fibrosis progression. In summary, our study provides a roadmap to leverage spatial metabolomics to understand foundational biology in pulmonary diseases.